Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
株価
$0.28545656
時価総額
$4.50M
変化(1日)
5.97%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)の利益
Jun 2024 時点の利益 TTM: $-12.93M
Acticor Biotech SAS の最新の財務報告によると、同社の現在の利益は $-12.93M です。2022 年には $-19.33M の利益を上げ、これは 2021 年の利益 $-16.54M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Acticor Biotech SAS の利益の推移(2010 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
同業他社の利益
企業 利益 利益の差
$20.46B -158,354.90%
DK
$4.64B -36,019.43%
US
$5.23B -40,564.29%
US
$2.14B -16,637.04%
BE
$1.61B -12,587.97%
AU